New hope for tough blood cancers: experimental drug enters human testing
NCT ID NCT05828589
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while also seeing if the drug can shrink tumors. Participants will take the drug alone, and the study will help decide if larger trials should move forward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032, China
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105-2108, United States
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, 300020, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health
New York, New York, 10016-2708, United States
-
Linear Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
Linyi Peoples Hospital
Linyi, Shandong, 276000, China
-
Mater Cancer Care Centre
South Brisbane, Queensland, QLD 4101, Australia
-
Mission Cancer and Blood
Waukee, Iowa, 50263, United States
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
Nyu Langone Health Perlmutter Cancer Center At Nyu Langone Hospital Long Island
Mineola, New York, 11501, United States
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100000, China
-
Pindara Private Hospital
Benowa, Queensland, QLD 4217, Australia
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004, China
-
Sibley Memorial Hospital Johns Hopkins Medicine
Washington D.C., District of Columbia, 20016, United States
-
Sidney Kimmel Comprehensive Cancer At Johns Hopkins
Baltimore, Maryland, 21287, United States
-
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Nanchang University Branch Xianghu
Nanchang, Jiangxi, 332000, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Peoples Hospital of Changzhou
Changzhou, Jiangsu, 213000, China
-
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242-1009, United States
-
Yichang Central Peoples Hospitaljiangnan Branch
Yichang, Hubei, 443001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Engineered immune cells take on tough lymphomas
- New transplant recipe aims to tame Graft-Versus-Host disease
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma